Key result
Normalizing the phosphorylation status of the myosin regulatory light chain rescues the hypertrophic cardiomyopathy phenotype caused by an RLC mutation.
Why the study?
Does normalizing the phosphorylation status of the myosin regulatory light chain rescue the hypertrophic cardiomyopathy phenotype in RLC mutation-induced HCM?
Does normalizing the phosphorylation status of the myosin regulatory light chain rescue the hypertrophic cardiomyopathy phenotype in RLC mutation-induced HCM?
Answers are grounded in this paper and cite their sources.
This commentary highlights preclinical evidence that normalizing myosin regulatory light chain phosphorylation can rescue the hypertrophic cardiomyopathy phenotype caused by an RLC mutation, identifying a potential therapeutic target.
A common cause of heart failure is hypertrophic cardiomyopathy (HCM) with a prevalence of at least 1 in 500 in adults (1); more recent data suggest that the prevalence of HCM may be as high as 1 in 200 (2). HCM is characterized by disorganized myocyte structure; formation of excess connective tissue (fibrosis); and, importantly, enlargement of cardiac myocytes that increases the ventricular wall thickness and lowers the ventricular chamber volume (1). Clinical manifestations of HCM vary among patients from mild shortness of breath to end-stage heart failure; HCM can also result in sudden cardiac arrest in young adults, especially in vigorously exercising athletes (3). In the majority of patients, HCM is an inherited disease (1). The first identified mutation to cause dilated cardiomyopathy was in myosin heavy chain, the molecular motor that underlies contraction of the heart (4). Since the discovery of this first mutation, more than 1,000 distinct gene mutations have been identified to cause HCM (5). Most of these gene mutations affect proteins that comprise the thin, thick, and titin myofilaments of the sarcomere (the contractile unit of the heart) (Fig. 1). HCM is therefore considered a disease of the sarcomere. It is not possible to revert HCM-causing mutations back to their WT state, and it is therefore important to study the mechanisms of disease that are triggered by the mutations and to identify therapeutic targets that could lessen disease progression and improve quality of life. Such targets have, so far, been elusive. The work of Yuan et al. (6) in PNAS shows that normalizing the phosphorylation status of the myosin regulatory light chain (RLC) rescues the HCM phenotype due to an RLC mutation.
No takes yet. Share an insight, caveat, or question.
Granzier et al. (2015) conducted an editorial in Hypertrophic cardiomyopathy (HCM) caused by a myosin regulatory light chain (RLC) mutation. Normalizing the phosphorylation status of the myosin regulatory light chain (RLC) was evaluated on Rescue of the hypertrophic cardiomyopathy (HCM) phenotype. Normalizing the phosphorylation status of the myosin regulatory light chain rescues the hypertrophic cardiomyopathy phenotype caused by an RLC mutation.
Synapse has enriched 10 related papers. Consider them for comparative context: